Discontinuing Bevacizumab in Patients with Glioblastoma: An Ethical Analysis

Glioblastoma (GBM) is a highly lethal malignant brain tumor that expresses proangiogenic factors, including vascular endothelial growth factor (VEGF). Bevacizumab (Avastin®; Genentech, Inc., South San Francisco, CA), a monoclonal antibody against VEGF, is routinely used in the U.S. to treat GBM pati...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Kesselheim, Jennifer C., Norden, Andrew D., Wen, Patrick Y., Joffe, Steven
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2011
Aiheet:
Medical Ethics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228073/
https://ncbi.nlm.nih.gov/pubmed/21948651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0047
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia